Actively Recruiting
Evaluating Datopotamab Deruxtecan with Other Cancer Agents for Solid Tumors in a Phase 12 Master Protocol Trial
Led by Daiichi Sankyo · Updated on 2026-10-22
268
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and antitumor activity of Datopotamab Deruxtecan Dato-DXd combined with other anticancer agents or alone in participants with solid tumors, specifically focusing on urothelial cancer and KRAS-mutant non-small cell lung cancer. The study includes two independent substudies, each with dose finding Phase 1 and signal finding Phase 2 phases to assess treatment effects and safety. Participants receive Dato-DXd intravenously combined with either enfortumab vedotin EV with or without pembrolizumab for urothelial cancer, or with the KRAS G12C inhibitor olomorasib orally for non-small cell lung cancer. Treatments are given according to dosing schedules determined in early study phases, with different groups receiving combinations or monotherapies based on tumor type and phase. During the study, participants undergo monitoring for adverse events, tumor response, and other clinical outcomes over approximately 2.9 years. Assessments include tumor imaging, laboratory tests, and evaluation of drug concentrations and immune responses. The research team tracks dose-limiting toxicities, treatment-related side effects, and tumor shrinkage to evaluate treatment impact and safety. Participants are followed for survival and disease control throughout the study period.
CONDITIONS
Brief Title
A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]
Research Team
C
Contact for Trial Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here